Risperidone-related weight gain: genetic and nongenetic predictors

Journal of Clinical Psychopharmacology
Hsien-Yuan LaneWen-Ho Chang

Abstract

A serious side effect of atypical antipsychotics is increased body weight, which leads to further morbidity and nonadherence to medication. It has been suggested that both genetic and nongenetic variables may influence antipsychotics-related weight gain. This study aimed to simultaneously explore the effects of multiple candidate genes and environment factors on body weight of schizophrenia patients who received risperidone, a commonly used atypical antipsychotic agent. One hundred twenty-three ethnically Han Chinese inpatients with acutely exacerbated schizophrenia were given risperidone monotherapy for up to 42 days. Body weight and clinical manifestations were assessed biweekly. Drug efficacy was measured by the Positive and Negative Syndrome Scale (PANSS), and safety was evaluated by the Extrapyramidal Symptom Rating Scale (ESRS) and the UKU Side Effect Rating Scale. We collected body weight as the response value. Potential prognostic factors were baseline body weight, age, sex, diagnosis subtypes, risperidone dosage, PANSS total scores, treatment duration (weeks 0-6), and 15 genetic variants [across 10 candidate genes: 5-HT1A, 5-HT2A, 5-HT2C, 5-HT6, D1, D2, D3, and alpha1-adrenergic receptors, brain-derived neurotrophic fa...Continue Reading

References

Jan 1, 1992·The American Journal of Psychiatry·R LeadbetterM Downs
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jul 1, 1987·Acta Psychiatrica Scandinavica·S C Newman, R C Bland
Jun 1, 1996·The American Journal of Psychiatry·J R BustilloA Breier
Dec 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M HummerW W Fleischhacker
Aug 1, 1997·Brain Research. Molecular Brain Research·P R BucklandP McGuffin
Apr 21, 1998·Biological Psychiatry·F R FrankenburgF Centorrino
Aug 10, 1999·Journal of Clinical Psychopharmacology·T Wetterling, H E Müssigbrodt
May 19, 2000·The Journal of Clinical Psychiatry·H Y LaneW H Chang
Mar 20, 2002·Psychiatric Genetics·Vicki L EllingrodStephan Arndt
Aug 31, 2002·The American Journal of Psychiatry·Hsien-Yuan LaneWen-Ho Chang
Dec 14, 2002·Lancet·Vincenzo S BasileJames L Kennedy
Dec 19, 2002·Biological Psychiatry·Xingqun NiJames L Kennedy
Jan 15, 2003·Psychopharmacology·Christine DuarteMarie-Hélène Thiébot
Apr 2, 2003·The American Journal of Psychiatry·Gavin P ReynoldsXiaoBin Zhang
Apr 30, 2004·Human Molecular Genetics·Marta RibasésXavier Estivill
May 4, 2004·The American Journal of Psychiatry·Anil K MalhotraJames L Kennedy
Jul 10, 2004·Psychopharmacology·Christoph U Correll, Anil K Malhotra
Jan 7, 2005·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Del D MillerStephan Arndt
Mar 3, 2005·The American Journal of Psychiatry·Paul R BucklandMichael C O'Donovan
Apr 12, 2005·Schizophrenia Research·Christoph EbenbichlerW Wolfgang Fleischhacker

❮ Previous
Next ❯

Citations

Jan 4, 2012·The Pharmacogenomics Journal·B AlmogueraUNKNOWN Spanish Consortium of Pharmacogenetics Research in Schizophrenia
Aug 30, 2008·Schizophrenia Bulletin·Maria J Arranz, Shitij Kapur
May 30, 2009·Diabetes, Obesity & Metabolism·Richard I G Holt, Robert C Peveler
Jan 1, 2011·BMJ Case Reports·Hira Ahmed, Hala Ali
Jan 1, 2011·Pharmacogenomics and Personalized Medicine·Tessa Jm WallaceDaniel J Müller
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell
Aug 17, 2011·Pharmacogenomics·Arne J RisseladaToine C G Egberts
Dec 18, 2013·Pharmacogenomics·Evangelia Eirini TsermpiniGeorge P Patrinos
Jan 19, 2013·Pharmacogenomics·Adrián LlerenaHumberto Fariñas
Oct 25, 2013·International Review of Psychiatry·C Anthony AltarDavid Mrazek
Nov 26, 2011·Expert Review of Clinical Pharmacology·Maria J Arranz, Janet C Munro
Jul 1, 2010·Expert Review of Neurotherapeutics·Lawrence Maayan, Christoph U Correll
Dec 18, 2010·Expert Opinion on Drug Metabolism & Toxicology·Jian-Ping Zhang, Anil K Malhotra
Feb 18, 2016·International Journal of Endocrinology·Amilton Dos Santos-JúniorPaulo Dalgalarrondo
Nov 17, 2015·The International Journal of Neuropsychopharmacology·Yoshiteru TakekitaAlessandro Serretti
Jan 7, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Trehani M FonsekaDaniel J Müller
Jun 5, 2014·Pharmacogenomics·Mark D Brennan
Dec 1, 2007·The International Journal of Neuropsychopharmacology·Antonio DragoAlessandro Serretti
Feb 20, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Yan-Feng ZouFang-Fang Liao
Feb 6, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Seunghyong RyuKyung Sue Hong
Apr 14, 2017·Journal of Pharmacology & Pharmacotherapeutics·Charanraj Goud AlladiKarthick Subramanian
Aug 30, 2008·JPEN. Journal of Parenteral and Enteral Nutrition·Gordon L Jensen
Mar 7, 2013·The Annals of Pharmacotherapy·Andrea L CartwrightMary H H Ensom
Apr 12, 2007·The Annals of Pharmacotherapy·Hossein KhaliliPadideh Ghaeli
Nov 4, 2017·Journal of Personalized Medicine·Ida AkaSara L Van Driest
Aug 18, 2010·The Pharmacogenomics Journal·D J MüllerJ L Kennedy
Sep 16, 2006·Journal of Clinical Psychopharmacology·Chih-Chiang ChiuMong-Liang Lu
Jan 17, 2007·Journal of Clinical Psychopharmacology·Jose de LeonGeorge M Simpson
Jul 17, 2007·Journal of Clinical Psychopharmacology·Hans MulderAntoine C G Egberts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here